Humans ; Myelodysplastic Syndromes ; diagnosis ; Prognosis

Humans ; Myelodysplastic Syndromes ; diagnosis ; therapy

Humans ; Myelodysplastic Syndromes ; diagnosis ; therapy

A total of 30 myelodysplastic syndromes (MDS) patients was analyzed to determine the clinical aspects and erythroid morphology in peripheral blood and bone marrow. The results are summarized as follows: 63.3% of patients was (50 years old. Male/Female ratio: 0.8. 46.7% were with lonely anemia and the rest were anemia combined with hemorrhages, infections, hepatosplenomegaly and lymphadenopathy. In peripheral blood: 63.4% of patients was with Hb<60g/l. 50% had normocrom - normocytic erythrocyte 96.7% of patients had dysmorphologic erythrocyte. In bone marrow: 46.6% were with hyperplasia of erythroid lineage, 33.6% were with hypoplasia of erythroid lineage, the rest (20%) were with normoplasia of erythroid lineage, 63.4% had dysmorphologic erythroblast, in which 36.7% was with ringed syderoblast
Myelodysplastic Syndromes ; blood ; diagnosis ; cytology ; Erythrocytes ; anemia

Child ; Humans ; Myelodysplastic Syndromes ; diagnosis ; Prognosis

Animals ; Humans ; Myelodysplastic Syndromes ; diagnosis ; genetics ; therapy

Humans ; Myelodysplastic Syndromes ; classification ; diagnosis ; Reference Standards

China ; Humans ; Myelodysplastic Syndromes ; diagnosis ; therapy

Anemia, Aplastic ; diagnosis ; Diagnosis, Differential ; Humans ; Myelodysplastic Syndromes ; diagnosis

Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by dysplasia in one or more linages of cells and increased risk of development of acute myeloid leukemia (AML). Along with the deeply understanding of myelodysplastic syndrome, the diagnosis standards of this disease experienced a leap in essence: from a single standard of morphological test in FAB to multiple detecting means in WHO standard of 2008, flow cytometry has been proposed as an adjunctive diagnostic test in the 2007 Vienna standards and the 2008 WHO standards. Recently, A heterogeneous spectrum of immunophenotypic abnormalities have been reported in MDS, and some of which are of great significance to the diagnosis, classification, prognosis assessment, and treatment of the disease. In the year of 2003, a flow cytometric scoring system (FCSS) was built to evaluate the prognosis of MDS patients, which was able to qualify the phenotypic aberrancies in the myelomonocytic, erythroid, and megakaryocytic lineage. It filled the gap of the international prognostic scoring system (IPSS) and the WHO classification-based prognostic scoring system (WPSS), and was of great value to the clinical diagnosis and treatment of MDS. In this article, the value of MDS immunophenotyping in diagnosis and prognosis evaluation of MDS is reviewed in term of MDS immunophenotypic abnormalities and flow cytometric scoring system.
Flow Cytometry ; Humans ; Immunophenotyping ; Myelodysplastic Syndromes ; classification ; diagnosis ; immunology ; Prognosis